Ingvild Jenssen Lægreid

Ingvild Jenssen Lægreid

Auto-generated profile, based on publicly available information

Ingvild Jenssen Lægreid

Nasjonal behandlingstjeneste for avansert trombocyttimmunologi, Laboratoriemedisin, Universitetssykehuset Nord-Norge

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
SJSilje Johansen
Silje Johansen
ILIngvild Jenssen Lægreid
Ingvild Jenssen Lægreid
SESiw Leiknes Ernstsen
Siw Leiknes Ernstsen
NANessar Ahmad Azrakhsh
Nessar Ahmad Azrakhsh
AKAstrid Olsnes Kittang
Astrid Olsnes Kittang
Håkon ReikvamHåkon Reikvam
Håkon Reikvam
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) has so far only been reported after adenovirus vector severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines. We report findings in a 25‐year‐old woman who presented with thrombocytopenia, venous thrombosis, elevated D‐dimer levels, and high levels of platelet‐activating antibodies to platelet factor 4‐polyanion complexes 10 days after Gardasil 9 vaccination for human papillomavirus (HPV). The patient exhibited clinical and laboratory features in line with the recently defined VITT syndrome, described after adenoviral vector vaccination to prevent coronavirus disease 2019. We report a case of VITT following HPV vaccination. This should raise awareness of the possibility of VITT also occurring after other vaccines, not exclusively adenoviral vector‐based SARS‐CoV‐2 vaccines.

3 August 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
AKAdam J. Kanack
Adam J. Kanack
ILIngvild J. Lægreid
Ingvild J. Lægreid
SJSilje Johansen
Silje Johansen
HRHåkon Reikvam
Håkon Reikvam
MAMaria Therese Ahlen
Maria Therese Ahlen
APAnand Padmanabhan
Anand Padmanabhan

14 September 2022 in Vox Sanguinis
Verified
Journal Article
Open access
ILIngvild Jenssen Lægreid
Ingvild Jenssen Lægreid
TWThomas Wilson
Thomas Wilson
KNKristoffer Hjertø Næss
Kristoffer Hjertø Næss
SESiw Leiknes Ernstsen
Siw Leiknes Ernstsen
VSVibeke Schou
Vibeke Schou
MAMirjana Grujic Arsenovic
Mirjana Grujic Arsenovic
Background and Objectives: The field of transfusion medicine started out with whole blood transfusion to treat severe anaemia and other deficiencies, and then transitioned to component therapy, largely leaving the practice, and experiences, of whole blood transfusions behind. Currently, the field is circling back and whole blood is gaining ground as an alternative to massive transfusion protocols.Materials and Methods: Herein we describe a severely anaemic paroxysmal nocturnal haemoglobinuria (PNH) patient initially suspected of suffering from renal haemorrhage, receiving a standard low‐titre group O whole blood transfusion during pre‐hospital transportation.Results: Following the transfusion, the patient suffered a clinically unmistakable haemolytic transfusion reaction requiring supportive treatment in the intensive care unit. Clinical observations are consistent with an acute haemolytic reaction. The haemolysis was likely due to minor incompatibility between the plasma from the transfused whole blood and the patient's PNH red cells. Recovery was uneventful.Conclusion: This revealed an unappreciated contraindication to minor incompatible whole blood transfusion, and prompted a discussion on the distinction between whole blood and erythrocyte concentrates, the different indications for use and the importance of emphasizing these differences. It also calls attention to patient groups where minor incompatibility can be of major importance.

21 November 2018 in Biomarker Research
Verified
Journal Article
Open access
PDF file
MBMarte Karen Brattås
Marte Karen Brattås
KLKyrre Lilleeng
Kyrre Lilleeng
RHRandi Hovland
Randi Hovland
ILIngvild Jenssen Lægreid
Ingvild Jenssen Lægreid
MVMarta Vorland
Marta Vorland
Håkon ReikvamHåkon Reikvam
Håkon Reikvam
A feature of myeloproliferative neoplasia is transforming to more aggressive and malignant myeloid neoplasia, including acute myeloid leukemia. Different pathogenesis mechanisms participate in transformation, including transformation of existing potential preleukemic clones, since JAK2-mutant myeloproliferative neoplasms often transform to JAK2 wild-type acute myeloid leukemia. Here, we present an 80 year old man with a JAK2-V617F mutant primary myelofibrosis. After 10 months the disease transform into a Philadelphia chromosome positive acute myeloid leukemia, detecting the cytogenetic aberration; t(9;22)(q34;q22) encoding the rare BCR-ABL1 fusion gene; e6a2. The patient had treatment response to tyrosine kinases, illustrating the potential benefits of such approach in treating these patients subset. The case illustrates the potential of leukemic transformation to Philadelphia chromosome positive myeloid malignancies from potential existing preleukemic clones, and the awareness of such an evolution among patients with myeloproliferative neoplasms. Tyrosine kinases have potential effect also in patients presenting without chronic myeloid leukemia and with rare BCR-ABL1 fusion transcripts, and should probably be a part of the treatment approach.

19 March 2022 in Transfusion
Verified
Journal Article
Open access
ILIngvild Jenssen Lægreid
Ingvild Jenssen Lægreid
MOMats Irgen Olsen
Mats Irgen Olsen
JHJon Inge Harr
Jon Inge Harr
RGRenathe Henriksen Grønli
Renathe Henriksen Grønli
TMTrude Victoria Mørtberg
Trude Victoria Mørtberg
MAMaria Therese Ahlen
Maria Therese Ahlen
Background Drug-induced immune thrombocytopenia (DITP) is a rare, but serious complication to a wide range of medications. Upon suspicion, one should do a thorough clinical evaluation following proposed diagnostic criteria and seek laboratory confirmation. If confirmed, it is important to ensure avoidance of the drug in the future. Study design and methods Herein, we describe a young adult male who experienced two bouts of severe thrombocytopenia following dental treatment. The thrombocytopenia was acknowledged due to unexpected hemorrhaging during the procedures. On both occasions, he was exposed to four different drugs, none commonly associated with DITP. After the second episode of severe procedural-related thrombocytopenia, an investigation into the cause was initiated. We describe the clinical approach to elucidate which of the four implicated drugs was responsible for thrombocytopenia and the laboratory work-up done to confirm that the reaction was antibody-mediated and identify the antibody's drug: glycoprotein specificity. An alternative drug was tested both in vivo and in vitro, to identify an option for future procedures. Results Sequential exposure revealed the local anesthetic substance articaine to induce thrombocytopenia. Laboratory work-up confirmed drug-dependent antibodies (DDAbs) with specificity for the glycoprotein Ib/IX complex, swiftly identified by a bead-based Luminex assay. Further investigations by monoclonal antibody immobilization of platelet antigens assay (MAIPA) revealed a probable GPIb binding site. An alternative local anesthetic, lidocaine, was deemed safe for future procedures. Conclusion Articaine can induce rapid-onset, severe immune-mediated thrombocytopenia causing bleeding complications. A modified bead-based Luminex platelet antigen assay proved a useful addition in the DITP-investigation.

10 October 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
ILIngvild Jenssen Lægreid
Ingvild Jenssen Lægreid
EHErin Mathiesen Hald
Erin Mathiesen Hald
MAMirjana Grujic Arsenovic
Mirjana Grujic Arsenovic
SESiw Leiknes Ernstsen
Siw Leiknes Ernstsen
KHKlara Asplund Högelin
Klara Asplund Högelin
MAMaria Therese Ahlen
Maria Therese Ahlen